OBJECTIVES: Interleukin-27 (IL-27) has been reported to inhibit type 2 T helper cell (Th2) response in allergic rhinitis (AR). However, its effects on group II innate lymphoid cells (ILC2) in AR are not fully understood. METHODS: Nineteen patients with AR and nineteen controls were enrolled in this study. The effects of IL-27 on ILC2 differentiation and function as well as the regulation of the IL-27 receptor (IL-27R) were analyzed by tritiated thymidine incorporation, enzyme-linked immunosorbent assay (ELISA), and real-time polymerase chain reaction (PCR), respectively. AR mice were used to confirm the role of IL-27 in vivo. RESULTS: The serum IL-27 protein expression in AR patients was significantly lower compared with controls. IL-27 decreased the ILC2 proliferation and type II cytokine secretion through the interaction with IL-27R. IL-27 also inhibited systemic and nasal ILC2 response of AR mice. CONCLUSION: IL-27 inhibited the proliferation and function of ILC2 in AR, implying that IL-27 may be used as new treatment target in AR.
OBJECTIVES: Interleukin-27 (IL-27) has been reported to inhibit type 2 T helper cell (Th2) response in allergic rhinitis (AR). However, its effects on group II innate lymphoid cells (ILC2) in AR are not fully understood. METHODS: Nineteen patients with AR and nineteen controls were enrolled in this study. The effects of IL-27 on ILC2 differentiation and function as well as the regulation of the IL-27 receptor (IL-27R) were analyzed by tritiated thymidine incorporation, enzyme-linked immunosorbent assay (ELISA), and real-time polymerase chain reaction (PCR), respectively. AR mice were used to confirm the role of IL-27 in vivo. RESULTS: The serum IL-27 protein expression in AR patients was significantly lower compared with controls. IL-27 decreased the ILC2 proliferation and type II cytokine secretion through the interaction with IL-27R. IL-27 also inhibited systemic and nasal ILC2 response of AR mice. CONCLUSION: IL-27 inhibited the proliferation and function of ILC2 in AR, implying that IL-27 may be used as new treatment target in AR.
Authors: C H Katelaris; B W Lee; P C Potter; J F Maspero; C Cingi; A Lopatin; M Saffer; G Xu; R D Walters Journal: Clin Exp Allergy Date: 2011-11-03 Impact factor: 5.018
Authors: David Artis; Alejandro Villarino; Michael Silverman; Weimian He; Elizabeth M Thornton; Sharon Mu; Shamin Summer; Todd M Covey; Elaine Huang; Hiroki Yoshida; Gary Koretzky; Michael Goldschmidt; Gary D Wu; Fred de Sauvage; Hugh R P Miller; Christiaan J M Saris; Phillip Scott; Christopher A Hunter Journal: J Immunol Date: 2004-11-01 Impact factor: 5.422
Authors: Caroline Diveu; Mandy J McGeachy; Katia Boniface; Jason S Stumhofer; Manjiri Sathe; Barbara Joyce-Shaikh; Yi Chen; Cristina M Tato; Terrill K McClanahan; René de Waal Malefyt; Christopher A Hunter; Daniel J Cua; Robert A Kastelein Journal: J Immunol Date: 2009-05-01 Impact factor: 5.422
Authors: Wenlong Liu; Renzhong Luo; Yanqiu Chen; Changzhi Sun; Jie Wang; Lifeng Zhou; Yan Li; Li Deng Journal: Pediatr Res Date: 2014-10-06 Impact factor: 3.756